Latest Conference Articles

Results of phase 2 study of AR-1105 in macular edema, secondary to retinal vein occlusion

Results of phase 2 study of AR-1105 in macular edema, secondary to retinal vein occlusion

October 21st 2021

ASRS

In his presentation at ASRS 2021, Dr. Michael Singer divulges the results of the phase 2 study of formulations used to decrease macular edema in patients with retinal vein occlusion.

Unpacking rho-kinase inhibition as a potential therapy for proliferative vitreoretinopathy

Unpacking rho-kinase inhibition as a potential therapy for proliferative vitreoretinopathy

October 19th 2021

ASRS

Leo Kim, MD, PhD, discusses his presentation at ASRS 2021, entitled "Rho-kinase inhibition on an in vitro patient-derived model of proliferative vitreoretinopathy."

PANOROMA elucidates effects of nonperfusion, leakage areas on DME, complications in NPDR

PANOROMA elucidates effects of nonperfusion, leakage areas on DME, complications in NPDR

October 15th 2021

ASRS

W. Lloyd Clark, MD, discusses his presentation at ASRS 2021, "Impact of Nonperfusion and Leakage Areas on Diabetic Macular Edema/Vision-Threatening Complications in Nonproliferative Diabetic Retinopathy (NPDR)."

Roundup of findings reported at ASRS 39th Annual Scientific Meeting

Roundup of findings reported at ASRS 39th Annual Scientific Meeting

October 13th 2021

ASRS

A review of studies, presentations and discussions at ASRS 2021 in San Antonio, Texas.

Dissecting real-world registry study of YUTIQ for chronic non-infectious posterior uveitis

Dissecting real-world registry study of YUTIQ for chronic non-infectious posterior uveitis

October 12th 2021

ASRS

Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

Discussing retina industry insights at Ophthalmology Innovation Summit

Discussing retina industry insights at Ophthalmology Innovation Summit

October 12th 2021

ASRS

Paul Hallen discusses the Retina Industry Insights panel at the Ophthalmology Innovation Summit in San Antonio, Texas.

OAKS and DERBY studies demonstrate efficacy of pegcetacoplan for Geographic Atrophy

OAKS and DERBY studies demonstrate efficacy of pegcetacoplan for Geographic Atrophy

October 11th 2021

ASRS

During the American Society of Retina Specialists 2021 annual meeting, David Boyer, MD, told attendees that pegcetacoplan used to treat geographic atrophy proved to be well tolerated by patients in the phase 3 DERBY and OAKS studies.

Study details Port Delivery System with ranibizumab in nAMD

Study details Port Delivery System with ranibizumab in nAMD

October 11th 2021

ASRS

In a presentation at the American Society of Retina Specialists 2021 annual meeting, Arshad Khanani, MD, MA, noted that investigators achieved results similar to those in patients treated with monthly ranibizumab injections for neovascular age-related macular degeneration.

Commercial OCT: Tracking macrophages in the macular circulation

Commercial OCT: Tracking macrophages in the macular circulation

October 10th 2021

ASRS

Speaking at the American Society of Retina Specialists 2021 annual meeting, Richard B. Rosen, MD, DSc (Hon) noted that clinical OCT and offers a new clinical biomarker for tracking the onset and progression of retinal vascular disease and the response to therapy.

Higher-order OCT analysis for inflammatory signal biomarkers in the HAWK study

Higher-order OCT analysis for inflammatory signal biomarkers in the HAWK study

October 10th 2021

ASRS

Justis P. Ehlers, MD, discusses the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.